Trial Parameters
Brief Summary
This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT). This research study involves: * NTS-WBRT (normal tissue sparing whole brain radiation therapy) * Memantine standard of care drug
Eligibility Criteria
Inclusion Criteria: * Any patient with a solid tumor diagnosis and any number of brain metastasis clinically indicated for cranial irradiation with whole brain radiation therapy * Age ≥ 18 * Karnofsky Performance Status ≥ 70 * Prior stereotactic radiosurgery (SRS) permissible per physician discretion * Prior craniotomy permissible per physician discretion. Protocol radiation therapy should be initiated ≥2 weeks after craniotomy. * Prior partial brain radiation therapy permissible if target volume \< 50% brain and per physician discretion * Expectant \> 6 months survival * Ability to understand and the willingness to sign a written informed consent document. * Fluency in English, able to complete questionnaires and neurocognitive testing * Ability to undergo MRI with gadolinium examination * Ability to return for follow-up examinations throughout the course of this study for a maximum of 2 years after radiation treatment completion * Any prior, concomitant, or post-radiotherapy systemic